Biopharma Dive recently published a series of articles on biotech bankruptcies. The first lists bankruptcies in 2019, while the other lists companies which are teetering towards bankruptcy. As the article notes,…
We're late to the this party, but HBM Partners issued their two annual reports on M&A Activity and New Drug Approvals. Both reports also have Excel files with raw…
At last month's Biotech Showcase, a panel discussion was held discussing different models for advancing assets without resorting to a license. The link to the discussion is here. It…
Twenty Five. That's it. What are we talking about? Some of the data in yesterday's excellent post by Bruce Booth on Early Stage Venture Scarcity really caught us by surprise. What…
According to Burrill & Company, July had the busiest week of biotech IPO activity ever, continuing a trend of heavy fundraising during 2013 so far: In all, 29…
We generally agree with the notion that many early-stage biotechs should be structured as LLCs instead of C corps. This short interview with Attorney Albert L. Sokol highlights one key…
As we read the continuing bad news regarding venture financing in biotech, we came across this bit of news from the UK: BioCity Nottingham-based CompanDX Limited, the Nottingham Trent University…
Thank goodness for Twitter. How else can one keep up with all of the news and happenings in our industry during the "slow" month of July? Here are a few…
AOL sells patents to Microsoft. Why? The reasons for AOL selling these patents are pretty clear: Shares of AOL surged as much as 45% Monday, hitting their highest point in…